The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 2, 2014, Pages 186-191

  Teng, R ^a   Mitchell, P D ^a   Butler, K ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

desmopressin; ticagrelor

Indexed keywords

DESMOPRESSIN; DRUG METABOLITE; TICAGRELOR; VON WILLEBRAND FACTOR;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLEEDING TIME; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; INHIBITION OF PLATELET AGGREGATION; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; PLATELET REACTIVITY; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

DESMOPRESSIN; TICAGRELOR;

ADENOSINE; ADULT; BLEEDING TIME; CROSS-OVER STUDIES; DEAMINO ARGININE VASOPRESSIN; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HEMOSTATICS; HUMANS; MALE; PLATELET AGGREGATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; YOUNG ADULT;

EID: 84895553730     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12130     Document Type: Article

References (20)

1. Gurbel PA, Bliden KP, Butler K, et al,. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor vs clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation, 2009; 120: 2577-2585.
2. Husted S, Emanuelsson H, Heptinstall S, et al,. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J, 2006; 27: 1038-1047.
3. Teng R, Butler K,. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol, 2010; 66: 487-496.
4. Wallentin L, Becker RC, Budaj A, et al,. Ticagrelor vs clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2009; 361: 1045-1057.
5. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A,. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet, 1977; 1: 869-872.
6. Hashemi S, Palmer DS, Aye MT, Ganz PR,. Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells. J Cell Physiol, 1993; 154: 496-505.
7. Mannucci PM, Levi M,. Prevention and treatment of major blood loss. N Engl J Med, 2007; 356: 2301-2311.
8. Gálvez A, Gõmez-Ortiz G, Díaz-Ricart M, et al,. Desmopressin (DDAVP) enhances platelet adhesion to the extracellular matrix of cultured human endothelial cells through increased expression of tissue factor. Thromb Haemost, 1997; 77: 975-980.
9. Mannucci PM,. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders: the first 20 years. Blood, 1988; 72: 1449-1455.
10. Leithäuser B, Zielske D, Seyfert UT, Jung F,. Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clin Hemorheol Microcirc, 2008; 39: 293-302.
11. Reiter RA, Mayr F, Blazicek H, et al,. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood, 2003; 102: 4594-4599.
12. Butler K, Teng R,. Pharmacokinetics, pharmacodynamics and safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol, 2010; 70: 65-77.
13. Sillén H, Cook M, Davis P,. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2010; 878: 2299-2306.
14. Anderson TL, Solem JO, Tengborn L, Vinge E,. Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation. Circulation, 1990; 81: 872-878.
15. Hirsh J, Glynn MF, Mustard JF,. The effect of platelet age on platelet adherence to collagen. J Clin Investig, 1968; 47: 466-473.
16. Rose EH, Aledort LM,. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med, 1991; 114: 563-568.
17. Endenburg SC, Hantgan RR, Lindeboom-Blokzijl L, et al,. On the role of von Willebrand factor in promoting platelet adhesion to fibrin in flowing blood. Blood, 1995; 86: 4158-4165.
18. Grau AJ, Reiners S, Lichy C, et al,. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke, 2003; 34: 849-854.
19. Fjellestad-Paulsen A, Hoglund P, Lundin S, Paulsen O,. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol, 1993; 38: 177-182.
20. Teng R, Oliver S, Hayes MA, Butler K,. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos, 2010; 38: 1514-1521.